• Skip to content
  • Accessibility help
Skip to content
Sign in
  • Guidance
  • Standards and indicators
  • Clinical Knowledge Summaries (CKS)
  • British National Formulary (BNF)
  • British National Formulary for Children (BNFC)
  • Life sciences
  • Skip More from NICE submenu

    Explore more from NICE

    • What NICE does
    • About us
    • Reusing our content
    • Implementing NICE guidance
    • News, blogs and podcasts
    • Contact us
    • Get involved
    • Careers

    • Join a committee
    • Comment on a consultation

My account

  • Consultation responses
  • Sign in

You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood conditions

Iptacopan for treating paroxysmal nocturnal haemoglobinuria

  • Technology appraisal guidance
  • Reference number: TA1000
  • Published:  04 September 2024
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

On this page

  1. Expected publication
  2. Declaration of interests
  3. Final draft guidance
  4. Invitation to participate
  5. Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6176

History

Documents created during the development process.

Expected publication

  • Equality impact assessment (guidance development) (PDF 158 KB)

    Published:
    04 September 2024

Declaration of interests

  • Register of interests (PDF 229 KB)

    Published:
    08 November 2024

Final draft guidance

  • Final draft guidance

  • Final draft guidance (PDF 239 KB)

    Published:
    17 May 2024
  • Committee papers (PDF 9.05 MB)

    Published:
    17 May 2024
  • Public committee slides (PDF 1.33 MB)

    Published:
    17 May 2024
  • Equality impact assessment (PDF 158 KB)

    Published:
    17 May 2024

Invitation to participate

  • Final scope (PDF 173 KB)

    Published:
    22 August 2023
  • Final stakeholder list (PDF 152 KB)

    Published:
    22 August 2023
  • NICE's response to comments on the draft scope and provisional stakeholder list (PDF 348 KB)

    Published:
    22 August 2023
  • Equality Impact Assessment (Guidance development) (PDF 127 KB)

    Published:
    22 August 2023

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6176

  • Draft matrix post referral (PDF 152 KB)

    Published:
    24 May 2023
  • Draft scope post referral (PDF 180 KB)

    Published:
    24 May 2023
Back to top
  • Guidance
  • Standards and indicators
  • Clinical Knowledge Summaries (CKS) Clinical Knowledge SummariesClinical Knowledge Summaries
  • British National Formulary (BNF) British National FormularyBritish National Formulary
  • British National Formulary for Children (BNFC) British National Formulary for ChildrenBritish National Formulary for Children
  • Life sciences
  • Library and knowledge services
  • What NICE does
  • Implementing NICE guidance
  • Get involved
  • About us
  • Careers
  • News, blogs and podcasts
  • Newsletters and alerts
  • Contact us
  • Leave feedback
  • Reusing our content
  • NICE UK Open Content Licence
  • Syndicate our content
  • Events
  • Facebook
  • X
  • YouTube
  • LinkedIn
  • Accessibility
  • Freedom of information
  • Glossary
  • Terms and conditions
  • Privacy notice
  • Cookies

© NICE 2025. All rights reserved. Subject to Notice of rights.